Fount of Information

ACROBiosystems社 NKG2A, a promising target within NK cell-based immunotherapy

この製品に関するご意見・ご照会・お問合せはこちら

NKG2A,_a_promising_target_within_NK_cell-based_immunotherapy_1.png

Products Support Resources Insights About Us

 

NKG2A,_a_promising_target_within_NK_cell-based_immunotherapy_2.jpg

 

NKG2A, a promising target within NK cell-based immunotherapy

 

The NKG2A/CD94/HLA-E pathway is considered to be an important immune checkpoint for NK cell-based immunotherapeutic strategies. NKG2A is expressed as a heterodimer with CD94. The ligands of NKG2A/CD94 heterodimeric receptors are non-classical MHC class I molecules. Engagement of NKG2A/CD94 receptor with peptide-presenting HLA-E results in the phosphorylation of ITIMs in NKG2A. Phosphorylated ITIMs are responsible for recruiting and activating intracellular phosphatase SHP-1 as well as SHP-2, thus suppressing the activation signals generated by activating receptors such as the T cell receptor (TCR) and NKG2D.

 

Therefore, disrupting the interaction of NKG2A with its ligands is shown to be effective in enhancing antitumor immune responses.

 

NKG2A,_a_promising_target_within_NK_cell-based_immunotherapy_3.jpg

 

To accelerate the research and drug development of NK cell-based immunotherapeutic, ACROBiosystems has developed a series of NKG2A/CD94 heterodimer proteins that suitable for immunization, antibody screening and more.

 

Learn More

 

  

★ Products lists

NKG2A,_a_promising_target_within_NK_cell-based_immunotherapy_4.jpg

 

★ Related products

LILRBs NKG2C & CD94 CD94 HLA-G

   

Click on the column for more information

 

Product features

 

  • Heterodimer structure and high purity (>90%) verified by MALS.
  • High homogeneity and high bioactivity verified by ELISA.
  • Protocols offered for free.

 

★Data

✔ Homogeneous structure and high purity (>90%) verified by MALS

NKG2A,_a_promising_target_within_NK_cell-based_immunotherapy_5.jpg 

✔ High Bioactivity

NKG2A,_a_promising_target_within_NK_cell-based_immunotherapy_6.jpgImmobilized Human NKG2A&CD94, Mouse IgG2a Fc Tag (Cat. No. NC4-H5253) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-NKG2A (Z270), Human IgG1 with a linear range of 0.2-8 ng/mL (QC tested).

 

Protocol

NKG2A,_a_promising_target_within_NK_cell-based_immunotherapy_7.jpg

Immobilized Biotinylated Human NKG2A&CD94, Fc,Avitag (Cat. No. NC4-H82F5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate. can bind various dilution ratio of HLA-E*01:03 HLA-A leader3-11 Tetramer-VMAPRTLVL-PE (QC tested).

 

Protocol

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。